The response to a given drug is largely determined by the patient’s genetic make-up. By incorporating relevant ‘pharmacogenomics’ approach in the set-up of clinical trials, patients can be selected in advance as responder or non-responder on the basis of an appropriate gene expression profile. This way, patients most likely to experience adverse drug reactions and/or poor drug efficacy can be excluded from the trial, thereby increasing the rate of potential responders and thus improving the chances of meeting the trial’s criteria.
To help pharmaceutical companies optimize their clinical trials, Ipsogen offers a unique combination of oncogenomic solutions including large scale gene expression profiling platforms using ultra-sensitive GMP biochips, high-throughput genotyping, haplotyping & sequencing and powerful bioinformatic tools.
Applications range from pharmacogenomic consulting to dissection of mechanisms of action, identification of biomarkers of efficacy / toxicity and elucidation of predictive gene signatures to optimize clinical use of anti-cancer drugs and assist in rational clinical trial design.
To discuss possible collaboration, please contact us.
